Ebenbuild is a Munich-based start-up that develops personalized lung simulation models—digital lung twins—built from patient-specific data to support intensive care treatment decisions. Its platform aims to replicate individual lungs so clinicians can evaluate different treatment options under real-life conditions to improve ventilation quality for mechanically ventilated ARDS patients. Ebenbuild will use BMBF grant funding (up to €900,000 as part of a €1.8M UBIC consortium award) to advance AI and simulation technologies to model heterogeneously damaged lungs. The company plans to work with multiple university hospitals in a multicenter study to collect and evaluate patient data and validate its digital twin models. Management frames this work as crucial for improving digitally supported decision-making in intensive care medicine and reducing ARDS mortality by enabling tailored ventilation strategies. There are no operating metrics reported in the article beyond the grant award; leadership includes CEO and co-founder Dr. Kei Müller. Ebenbuild develops patient-specific lung simulation models — “digital twins” — that predict airflow, pressure and tissue strain to guide mechanical ventilation for ICU patients with ARDS. The software uses patient data such as medical images to generate virtual models and evaluate digital biomarkers for individualized treatment decisions. The company was founded in April 2019 following research at the Technical University of Munich and is based in Munich. Ebenbuild says its product is intended to reduce lung damage, shorten hospital stays and improve treatment outcomes and mortality for ARDS patients. The team plans to use new funding to advance its prototype toward clinical application, market launch and medicinal product approval. Financially, Ebenbuild announced a seven-figure seed financing round totaling €2.5 million.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2023